- Press Releases
- Notices
Press Releases To List
-
- Jan.06.2025R & D
- U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications
-
- Dec.27.2024R & D
- Ono Receives Supplemental Approval of Opdivo® in Combination with Cisplatin and Gemcitabine for Treatment of Unresectable Urothelial Carcinoma in Japan
-
- Dec.25.2024R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
-
- Dec.24.2024Sustainability
- ONO Earned Top Score in the Pharmaceutical Sector of the Dow Jones Sustainability Index Selected for the World Index and Asia Pacific Index for Five Straight Years
-
- Dec.23.2024R & D
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Notices To List
-
- Oct.01.2024Corporate
- ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan
-
- Sep.30.2024Corporate
- Corporate Report 2024 has been released.
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
-
- Jun.20.2024Corporate
- Notice to Resolutions Passed at The 76th Ordinary General shareholders’ Meeting
-
- May.23.2024Corporate
- Notice to Convene the 76th Ordinary General Shareholders' Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
